Pacira BioSciences (PCRX) Accumulated Expenses (2010 - 2026)

Pacira BioSciences' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $85.0 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 6.1% year-over-year to $85.0 million; the TTM figure through Mar 2026 stood at $85.0 million (up 6.1% YoY), while the FY2025 annual figure was $95.6 million, up 19.32% from the prior year.
• Accumulated Expenses was $85.0 million for Q1 2026 at Pacira BioSciences, down from $95.6 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $95.6 million in Q4 2025 to a low of $56.2 million in Q2 2023.
• Historically, Accumulated Expenses has averaged $74.9 million across 5 years, with a median of $76.4 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses surged 74.5% in 2022, then decreased 29.7% in 2023.
• A 5-year view of Accumulated Expenses shows it stood at $89.8 million in 2022, then slipped by 28.45% to $64.2 million in 2023, then advanced by 24.72% to $80.1 million in 2024, then climbed by 19.32% to $95.6 million in 2025, then retreated by 11.13% to $85.0 million in 2026.
• The last three Accumulated Expenses figures came in at $85.0 million (Q1 2026), $95.6 million (Q4 2025), and $79.6 million (Q3 2025), per Business Quant data.